SCHEMBL2521920

SCHEMBL2521920

CC(C)(C)OC(=O)NC1(CNc2ccc(I)cn2)CCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.43
SMO Q99835 1/20 0.38
NAMPT P43490 1/20 0.33
PPIA P62937 1/20 0.33
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32
GRIN2B Q13224 1/20 0.32
HDAC1 Q13547 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
SYK P43405 1/20 0.31
HCAR3 P49019 1/20 0.31
AAK1 Q2M2I8 1/20 0.31
EDNRA P25101 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
IRAK1 P51617 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18519550 0.78 MAPT (0.50)
SCHEMBL29518465 0.77 SSTR4 (0.37) P2RX7PPIAGSK3BDYRK1AGABRA1
SCHEMBL22825882 0.77 SSTR4 (0.37) P2RX7PPIAGSK3BDYRK1AGABRA1
SCHEMBL4491782 0.76 BCHE (0.46) HCAR3STK17BSTK17A
SCHEMBL30231113 0.75 GSK3B (0.44) NAMPTGSK3BDYRK1AGRIN2BHDAC1
SCHEMBL4398253 0.75 GSK3B (0.44) NAMPTGSK3BDYRK1AGRIN2BHDAC1
SCHEMBL2714677 0.74 KIT (0.38) P2RX7GSK3BDYRK1AGABRA1GABRG2
SCHEMBL12810107 0.74 P2RX7 (0.37) P2RX7SMOPPIASYKAAK1
SCHEMBL1666761 0.74 P2RX7 (0.45) P2RX7SMOPPIA
SCHEMBL2391676 0.73 AKT1 (0.36) GSK3BDYRK1AGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315498-B2 Arlethynyl derivatives HOFFMAN-LA ROCHE INC. (US) 2016-04-19 US disclosed
US-9315498-B2 Arlethynyl derivatives HOFFMAN-LA ROCHE INC. (US) 2016-04-19 US disclosed
US-9315498-B2 Arlethynyl derivatives HOFFMAN-LA ROCHE INC. (US) 2016-04-19 US disclosed
EP-2558457-B1 ARYLETHYNYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2016-03-09 EP disclosed
EP-2558457-B1 ARYLETHYNYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2016-03-09 EP disclosed
US-20140155602-A1 Arlethynyl Derivatives HOFFMANN-LA ROCHE INC. (US) 2014-06-05 US disclosed
US-8618296-B2 Arylethynyl derivatives HOFFMANN-LA ROCHE INC. (US) 2013-12-31 US disclosed
US-20130274464-A1 Arylethynyl Derivatives F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 US disclosed
US-20130274464-A1 Arylethynyl Derivatives F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 US disclosed
US-20130274464-A1 Arylethynyl Derivatives F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 US disclosed
US-20130178456-A1 ARYLETHYNYL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-07-11 US disclosed
US-8420661-B2 Arylethynyl derivatives HOFFMANN-LA ROCHE INC. (US) 2013-04-16 US disclosed
US-8420661-B2 Arylethynyl derivatives HOFFMANN-LA ROCHE INC. (US) 2013-04-16 US disclosed
US-8420661-B2 Arylethynyl derivatives HOFFMANN-LA ROCHE INC. (US) 2013-04-16 US disclosed
EP-2558457-A1 ARYLETHYNYL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2013-02-20 EP disclosed
WO-2011128279-A1 ARYLETHYNYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-10-20 WO disclosed
WO-2011128279-A1 ARYLETHYNYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-10-20 WO disclosed
US-20110251169-A1 Arylethynyl derivatives HOFFMANN-LA ROCHE, INC. 2011-10-13 US disclosed
US-20110251169-A1 Arylethynyl derivatives HOFFMANN-LA ROCHE, INC. 2011-10-13 US disclosed
US-20110251169-A1 Arylethynyl derivatives HOFFMANN-LA ROCHE, INC. 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178456-A1 ARYLETHYNYL DERIVATIVES GRM5, GRM1, GRM3 P2RX7 318/4885SMO 1855/4885NAMPT 4087/4885
US-20140155602-A1 Arlethynyl Derivatives GRM5, GRIK5, GRM1 P2RX7 421/4885SMO 1433/4885NAMPT 4627/4885
US-20130274464-A1 Arylethynyl Derivatives GRM5, GRM1, GRM3 P2RX7 318/4885SMO 1855/4885NAMPT 4087/4885
US-20110251169-A1 Arylethynyl derivatives GRM5, GRM1, GRM3 P2RX7 318/4885SMO 1855/4885NAMPT 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.